This educational activity is specifically designed for oncologists, hematologists, and other healthcare professionals (including nurses and pharmacists) interested and/or involved in the care of patients with cancer. No specialized knowledge or skill other than a general familiarity of oncology and hematology and its treatment is required for successful participation in this activity.
This Web offering is an electronic representation of the 2008 NOCR Annual Meeting that was held in Las Vegas on March 5-6, 2008. A number of interesting and contemporary discussions by well-known thought leaders offer an update on state-of-the-art cancer therapies and novel treatments on the horizon.
After completing this activity, the participant will be able to:
- Explain how new and emerging therapies and approaches are changing the practice of oncology
- Describe and evaluate areas of clinical controversy in the management of various malignancies
- Analyze the impact of new clinical data and discuss how this emerging data can be applied to current clinical practice within the context of survival outcomes and quality of life issues
- Explore emerging areas of knowledge and understanding in the molecular biology of oncology and how these areas will likely shape future clinical practice
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options including but not limited to the use of generic names to ensure impartiality.
All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.
1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support
| Kenneth C. Anderson, MD, MA |
Millennium Pharmaceuticals, Inc1,2,3 |
| James Armitage, MD |
Genitope Corporation2; GlaxoSmithKline2; MGI PHARMA, INC5;
Roche Laboratories Inc2; Ziopharm Oncology, Inc2 |
| Dean F. Bajorin, MD |
Pfizer Inc1 |
| William Blum, MD |
MGI PHARMA, INC2,3; Pharmion Corporation1 |
| Jorge Cortes, MD |
Breakthrough Therapeutics, LLC1; ChemGenex Pharmaceuticals1; MERCK & CO, Inc.1; Tibotec Pharmaceuticals Limited1;
The Vaccine Company1
|
| Walter J. Curran, Jr, MD, FACR |
ImClone Systems Incorporated2; OSI Pharmaceuticals2 |
| Robert Dreicer, MD, FACP |
Bayer HealthCare Corporation1; Dendreon Corporation2;
MERCK & CO, Inc.2 |
| Axel Grothey, MD |
Roche Laboratories Inc.2 |
| Daniel G. Haller, MD |
Roche Laboratories Inc.1,2 |
| Gary R. Hudes, MD |
Pfizer Inc2 |
| David M. Jablons, MD |
OSI Pharmaceuticals3 |
| Thomas J. Lynch, Jr, MD |
Exelixis Inc1 ; ImClone Systems Incorporated1; OSI Pharmaceuticals1 |
| David G. Maloney, MD, PhD |
Biogen Idec Inc2; Favrille, Inc.2; GlaxoSmithKline2;
Millennium Pharmaceuticals, Inc.2 |
| John L. Marshall, MD |
Pfizer Inc1,2,3; Roche Laboratories1,2,3 |
| Ruth M. O’Regan, MD |
Abraxis Oncology1; Pfizer Inc3 |
| Robert Z. Orlowski, MD, PhD |
Millennium Pharmaceuticals, Inc.2; Ortho-Biotech Products, L.P.2; Proteolix, Inc.2 |
| Hope S. Rugo, MD |
GlaxoSmithKline1; Pfizer Inc1 |
| David P. Steensma, MD |
MGI PHARMA, INC1; OsteoBiologics, Inc.1 |
| Douglas Yee, MD |
MERCK & CO, Inc.1; Pfizer Inc.1 |
| Andrew X. Zhu, MD, PhD |
Bayer HealthCare Corporation2 |
The following speakers have reported an affiliation with the supporters of this conference:
| Kenneth C. Anderson, MD, MA |
Celgene Corporation1,2,3; Novartis Pharmaceuticals Corporation2 |
| James Armitage, MD |
Celgene Corporation2; Genentech BioOncology2 |
| Dean F. Bajorin, MD |
Bristol-Myers Squibb Company1,2; Eli Lilly and Company1,2; Genentech BioOncology1 |
| Jorge Cortes, MD |
Bristol-Myers Squibb Company1; Novartis Pharmaceuticals Corporation1; Wyeth Pharmaceuticals, Inc1 |
| Walter J. Curran, Jr, MD, FACR |
Bristol-Myers Squibb Company2; Genentech BioOncology2; Eli Lilly and Company2 |
| Robert Dreicer, MD, FACP |
Celgene Corporation1; Eli Lilly and Company1;
Novartis Pharmaceuticals Corporation2 |
| Axel Grothey, MD |
Amgen Inc.2; Bristol-Myers Squibb Company2;
Genentech BioOncology1,2; sanofi-aventis1,2 |
| Daniel G. Haller, MD |
Bristol-Myers Squibb Company1; Genentech BioOncology2; sanofi-aventis2 |
| Gary R. Hudes, MD |
Genentech BioOncology2; Wyeth Pharmaceuticals, Inc2 |
| David M. Jablons, MD |
Genentech BioOncology3; Eli Lilly and Company3 |
| Thomas J. Lynch, Jr, MD |
Genentech BioOncology1,2,3; Eli Lilly and Company1;
sanofi-aventis. U.S.1 |
| David G. Maloney, MD, PhD |
Genentech BioOncology1,2; Gloucester Pharmaceuticals2 |
| John L. Marshall, MD |
Amgen Inc.1,2,3; Bristol-Myers Squibb Company1,2,3; Genentech BioOncology1,2,3; sanofi-aventis, U.S.1,2,3 |
| Bruce D. Minsky, MD |
Bristol-Myers Squibb Company2; Genentech BioOncology2; sanofi-aventis2 |
| Ruth M. O’Regan, MD |
Genentech BioOncology3; Eli Lilly and Company3;
sanofi-aventis, U.S.1 |
| Hope S. Rugo, MD |
Bristol-Myers Squibb Company1; Genentech BioOncology1; Novartis Pharmaceuticals Corporation1 |
| Robert Z. Orlowski, MD, PhD |
Celgene Corporation2 |
| David P. Steensma, MD |
Amgen Inc.1 |
| Andrew X. Zhu, MD, PhD |
Genentech BioOncology2 |
The following speakers do not report any affiliation:
Harold J. Burstein, MD, PhD
Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:
Keith Steward, MD, MBA, owns shares of Pfizer Inc. and Johnson & Johnson, as well as stock options for AmerisourceBergen.
Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.
Kenneth Richardson, MD, Bradley Bongiovanni, ND, and Becky Lynch, RN, own stock options for AmerisourceBergen.
Moderator
James Epstein, MD
Imedex, LLC
Alpharetta, Georgia
Faculty
Kenneth C. Anderson, MD, MA
Dana-Farber Cancer Institute
Boston, Massachusetts
James Armitage, MD
University of Nebraska Medical Center
Omaha, Nebraska
Dean F. Bajorin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
William Blum, MD
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Harold J. Burstein, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts
Jorge Cortes, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Walter J. Curran, Jr, MD, FACR
Emory University
Atlanta, Georgia
Robert Dreicer, MD, FACP
Cleveland Clinic
Cleveland, Ohio
Axel Grothey, MD
Mayo Clinic College of Medicine
Rochester, Minnesota
Daniel G. Haller, MD
University of Pennsylvania
Philadelphia, Pennsylvania
Gary R. Hudes, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
David M. Jablons, MD
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Thomas J. Lynch, Jr, MD
Massachusetts General Hospital
Boston, Massachusetts
David G. Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, Washington
John L. Marshall, MD
Georgetown University Lombardi Cancer Center
Washington, District of Columbia
Bruce D. Minsky, MD
University of Chicago Medical Center
Chicago, Illinois
Ruth M. O’Regan, MD
Emory University
Atlanta, Georgia
Robert Z. Orlowski, MD, PhD
The University of Texas, M. D. Anderson Cancer Center
Houston, Texas
Hope S. Rugo, MD
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California
David P. Steensma, MD
Mayo Clinic
Rochester, Minnesota
Douglas Yee, MD
University of Minnesota Cancer Center
Minneapolis, Minnesota
Andrew X. Zhu, MD, PhD
Massachusetts General Hospital
Boston, Massachusetts
All materials are included with the permission of the authors.
This activity is sponsored by Imedex, LLC.
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 10.75 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.
For questions regarding the accreditation of this activity, please contact
Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.
The opinions expressed in this email case discussion are the opinions of the authors and do not necessarily reflect the opinions of Imedex or the American School of Oncology.
The following companies have provided unrestricted educational grants in support of this activity: Amgen Inc; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Genentech BioOncology; Gloucester Pharmaceuticals; Novartis Pharmaceuticals Corporation; sanofi-aventis, U.S.; and Wyeth Pharmaceuticals, Inc.
|
